DealsJun 2, 2026, 07:07 AM
Travere Licenses Civorebrutinib from Everest for $112.5M Upfront
AI Summary
Travere Therapeutics, Inc. has entered into an exclusive license and collaboration agreement with Everest Medicines (Singapore) Pte. Ltd. for civorebrutinib, a BTK inhibitor. Under the agreement, Travere gains exclusive rights to develop and commercialize the drug in all countries outside of China and certain East and Southeast Asian countries. Travere will make an upfront payment of $112.5 million and Everest is eligible for up to $1.03 billion in milestone payments, plus tiered royalties on net sales.
Key Highlights
- Travere Therapeutics entered an exclusive license and collaboration agreement with Everest Medicines for civorebrutinib.
- Travere will pay Everest an upfront payment of $112.5 million.
- Everest is eligible to receive up to approximately $1.03 billion in additional clinical, regulatory, and commercial milestone payments.
- Travere will pay Everest tiered royalties on net sales of Products in the Territory, ranging from high single-digit to double-digit percentages.
- The agreement grants Travere exclusive rights to develop and commercialize civorebrutinib outside of China and certain East/Southeast Asian countries.
- Civorebrutinib (EVER001) is a covalent reversible Bruton's tyrosine kinase (BTK) inhibitor.
- Both parties are prohibited from developing, manufacturing, or commercializing any competing BTK product in the Field for ten years.
Price Impact
More from TVTX